Zidovudine toxicity in uninfected healthcare workers

American Journal of Medicine

Volumn 102, Issue 5 B, 1997, Pages 58-62

  Ippolito, Giuseppe ^a   Puro, Vincenzo ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

ANOREXIA; ARTHRALGIA; ASTHENIA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEVER; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OCCUPATIONAL EXPOSURE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; STOMACH PAIN; VERTIGO; VOMITING;

ANTI-HIV AGENTS; DIDANOSINE; DRUG THERAPY, COMBINATION; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; ITALY; OCCUPATIONAL EXPOSURE; REGISTRIES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; ZALCITABINE; ZIDOVUDINE;

EID: 0030787519     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00064-8     Document Type: Conference Paper

References (11)

1. Ippolito G, Puro V, De Carli G, and the Italian Study Group on Occupational Risk of HIV Infection. The risk of occupational human immunodeficiency virus infection in health care workers: Italian multicenter study. Arch Intern Med. 1993;153:1451-1458.
2. Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med. 1993;118:913-919.
3. Hirsch MS, D'Aquila RT. Therapy for human immunodeficiency virus infection. N Engl J Med. 1993;328:1686-1695.
4. Anonymous. New drugs for HIV infection. Medical Letter. 1996;38:35-37.
5. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
6. Niu MT, Stein DS, Schnittmann SM. Primary human immurodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis. 1993;168:1490-1501.
7. Puro V, Ippolito G, Guzzanti E, et al. Zidovudine prophylaxis after accidental exposure to HIV: the Italian experience. AIDS. 1992;6:963-969.
8. Fahrner R, Beekman SE, Koziol DE, et al. Safety of zidovudine (ZDV) administered as postexposure prophylaxis to health care workers (HCW) sustaining HIV-related occupational exposure (OE). (Abstr. I152.) Presented at the 34th Interscience Conference on antimicrobial Agents and Chemotherapy, Orlando, Florida, 1994.
9. Forseter G, Joline C, Wormser GP. Tolerability, safety, and acceptability of zidovudine prophylaxis in health care workers. Arch Intern Med. 1994;154:2746-2749.
10. White A, Andrews E, Eldrige R, et al. Birth outcomes following zidovudine therapy in pregnant women. MMWR. 1994;43:409, 415, 416.
11. Cote TR, Biggar RJ. Does zidovudine cause non-Hodgkin's lymphoma? AIDS. 1995;9:404-405.